Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

  • Lázaro García, Conxi
  • ProCURE
  • Genetic Counseling Unit, Hereditary Cancer Program
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease(1). We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 x 10(-8) with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

  • Fachal, Laura
  • Aschard, Hugues
  • Beesley, Jonathan
  • Barnes, Daniel R.
  • Allen, Jamie
  • Kar, Siddhartha
  • Pooley, Karen A.
  • Dennis, Joe
  • Michailidou, Kyriaki
  • Turman, Constance
  • Soucy, Penny
  • Lemaçon, Audrey
  • Lush, Michael
  • Tyrer, Jonathan P.
  • Ghoussaini, Maya
  • Moradi Marjaneh, Mahdi
  • Jiang, Xia
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alonso, M. Rosario
  • Andrulis, Irene L.
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arason, Adalgeir
  • Arndt, Volker
  • Aronson, Kristan J.
  • Arun, Banu K.
  • Auber, Bernd
  • Auer, Paul L.
  • Azzollini, Jacopo
  • Balmaña, Judith
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel
  • Beeghly-Fadiel, Alicia
  • Benitez, Javier
  • Bermisheva, Marina
  • Białkowska, Katarzyna
  • Blanco, Amie M.
  • Blomqvist, Carl
  • Blot, William
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bolla, Manjeet K.
  • Bonanni, Bernardo
  • Borg, Ake
  • Bosse, Kristin
  • Brauch, Hiltrud
  • Brenner, H.
  • Briceno, I.
  • Caldés, T.
  • Castelao, J. E.
  • Hoya, Miguel de la
  • Diez, Orland
  • Durán, Mercedes
  • Gago-Dominguez, Manuela
  • García-Saenz, José Ángel
  • González-Neira, Anna
  • Moreno, Fernando
  • Muñoz-Garzón, Víctor M.
  • Osorio, Ana
  • Pujana, Miguel Ángel
  • Romero, Atocha
  • Sánchez-Herrero, Estela
  • Santamariña, Marta
  • Teulé, Alex
  • Vega, Ana I.
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic feature annotations. We defined 205 independent risk-associated signals with the set of credible causal variants in each one. In parallel, we used a Bayesian approach (PAINTOR) that combines genetic association, linkage disequilibrium and enriched genomic features to determine variants with high posterior probabilities of being causal. Potentially causal variants were significantly over-represented in active gene regulatory regions and transcription factor binding sites. We applied our INQUSIT pipeline for prioritizing genes as targets of those potentially causal variants, using gene expression (expression quantitative trait loci), chromatin interaction and functional annotations. Known cancer drivers, transcription factors and genes in the developmental, apoptosis, immune system and DNA integrity checkpoint gene ontology pathways were over-represented among the highest-confidence target genes., This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under Marie Sklodowska-Curie grant agreement number 656144. Genotyping of the OncoArray was principally funded from three sources: the PERSPECTIVE project (funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie de la Science et de l’Innovation du Québec’ (through Genome Québec) and the Quebec Breast Cancer Foundation); the NCI Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative and the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project (NIH grants U19 CA148065 and X01HG007492); and Cancer Research UK (C1287/A10118, C8197/A16565 and C1287/A16563). BCAC is funded by Cancer Research UK (C1287/A16563), by the European Community’s Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175) (COGS) and by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements 633784 (B-CAST) and 634935 (BRIDGES). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710), the Canadian Institutes of Health Research for the ‘CIHR Team in Familial Risks of Breast Cancer’ program, and the Ministry of Economic Development, Innovation and Export Trade of Quebec (grant PSR-SIIRI-701). Combining of the GWAS data was supported in part by NIH Cancer Post-Cancer GWAS initiative grant U19 CA 148065 (DRIVE; part of the GAME-ON initiative).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

  • Lázaro García, Conxi
  • ProCURE
  • Genetic Counseling Unit, Hereditary Cancer Program
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease(1). We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 x 10(-8) with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.